In 2010, the FDA approved a change in the dosing for Prezista (darunavir) for people who have been on HIV treatment before. This could possibly help people take their regimens on schedule every day. However, the dosing change should not be attempted in people with known resistance mutations to Prezista.
The current dosing of Prezista for treatment experienced people is twice a day. In the ODIN study, one group continued to take Prezista twice a day for 48 weeks while a second group changed their dose to once a day.
In those whose HIV showed no resistance to Prezista, the drug controlled HIV to undetectable levels for the 48 weeks. Although this is an improvement in dosing and convenience, and will hopefully suppress HIV for more than a year, more attention may need to be paid to monitoring resistance and viral load while on once a day Prezista for treatment experienced.